ArticleActa neurochirurgica2026
Pharmacovigilance study of spinal epidural hematoma reports associated with direct oral anticoagulants and warfarin.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpontaneous spinal epidural hematoma (SEH) is a rare but potentially catastrophic condition that may be worsened by anticoagulation. We evaluated reporting patterns and signal strength of SEH associated with warfarin and DOACs using pharmacovigilance database analysis.
methodsA retrospective disproportionality analysis was conducted using the FDA Adverse Event Reporting System (FAERS) from Q4/2003 to Q2/2025. Reports of SEH associated with warfarin, rivaroxaban, apixaban, and dabigatran were analyzed. Signal detection employed Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and chi-squared analysis with Yates' correction. A signal was significant if n > 3, χ2 > 4, and PRR > 2.
resultsA total of 143 SEH reports were identified. Warfarin accounted for 83 cases, rivaroxaban 28, apixaban 25, and dabigatran 7. All demonstrated significant disproportionality signals. Warfarin showed the strongest signal (ROR 29.2, 95% CI 22.9-37.1), followed by rivaroxaban (ROR 8.09), dabigatran (ROR 5.75), and apixaban (ROR 4.78). Warfarin patients were younger (mean 62 years) than DOAC users (75-76 years). Mortality occurred in 9 warfarin and 8 rivaroxaban cases. Atrial fibrillation was the most frequent indication for anti-coagulation.
conclusionsThis pharmacovigilance study identified disproportionate reporting signals for spinal epidural hematoma across warfarin and DOACs, with stronger signals observed for warfarin and rivaroxaban. Given the inherent limitations of spontaneous reporting databases, these findings should be interpreted as hypothesis-generating rather than causal. Further controlled studies are needed to determine true incidence and comparative risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.